|
1
|
Suppiah V, Moldovan M, Ahlenstiel G, Berg
T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell
E, et al: IL28B is associated with response to chronic hepatitis C
interferon-alpha and ribavirin therapy. Nat Genet. 41:1100–1104.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tanaka Y, Nishida N, Sugiyama M, Kurosaki
M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S,
et al: Genome-wide association of IL28B with response to pegylated
interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat
Genet. 41:1105–1109. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang H, Jiang YF, He SM, Sun J, Gu Q,
Feng XW, Du B, Wang W, Shi XD, Wang CY, et al: Etiology and
prevalence of abnormal serum alanine aminotransferase levels in a
general population in Northeast China. Chin Med J (Engl).
124:2661–2668. 2011.PubMed/NCBI
|
|
4
|
Hinrichsen H, Benhamou Y, Wedemeyer H,
Reiser M, Sentjens RE, Calleja JL, Forns X, Erhardt A, Crönlein J,
Chaves RL, et al: Short-term antiviral efficacy of BILN 2061, a
hepatitis C virus serine protease inhibitor, in hepatitis C
genotype 1 patients. Gastroenterology. 127:1347–1355. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pawlotsky JM, Chevaliez S and McHutchison
JG: The hepatitis C virus life cycle as a target for new antiviral
therapies. Gastroenterology. 132:1979–1998. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jacobson IM, McHutchison JG, Dusheiko G,
Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci
P, Flisiak R, et al: Telaprevir for previously untreated chronic
hepatitis C virus infection. N Engl J Med. 364:2405–2416. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ,
Yang SS, Hsu CS, Tseng TC, Wang CC, Lai MY, et al: Pegylated
interferon-alpha-2a plus ribavirin for treatment-naive Asian
patients with hepatitis C virus genotype 1 infection: A
multicenter, randomized controlled trial. Clin Infect Dis.
47:1260–1269. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
de Segadas-Soares JA, Villela-Nogueira CA,
Perez RM, Nabuco LC, Brandão-Mello CE and Coelho HS: Is the rapid
virologic response a positive predictive factor of sustained
virologic response in all pretreatment status genotype 1 hepatitis
C patients treated with peginterferon-alpha2b and ribavirin? J Clin
Gastroenterol. 43:362–366. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thomas DL, Thio CL, Martin MP, Qi Y, Ge D,
O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, et al: Genetic
variation in IL28B and spontaneous clearance of hepatitis C virus.
Nature. 461:798–801. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ahlenstiel G, Booth DR and George J: IL28B
in hepatitis C virus infection: Translating pharmacogenomics into
clinical practice. J Gastroenterol. 45:903–910. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thompson AJ, Muir AJ, Sulkowski MS, Ge D,
Fellay J, Shianna KV, Urban T, Afdhal NH, Jacobson IM, Esteban R,
et al: Interleukin-28B polymorphism improves viral kinetics and is
the strongest pretreatment predictor of sustained virologic
response in genotype 1 hepatitis C virus. Gastroenterology.
139:120–129, e18. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Clark PJ, Thompson AJ and McHutchison JG:
IL28B genomic-based treatment paradigms for patients with chronic
hepatitis C infection: The future of personalized HCV therapies. Am
J Gastroenterol. 106:38–45. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Melian EB and Plosker GL: Interferon
alfacon-1: A review of its pharmacology and therapeutic efficacy in
the treatment of chronic hepatitis C. Drugs. 61:1661–1691. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Moore CM, George M and Van Thiel DH:
Consensus interferon used to treat prior partial-responders to
pegylated interferon plus ribavirin. Dig Dis Sci. 56:3032–3037.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cai Y, Zhang Z, Fan K, Zhang J, Shen W, Li
M, Si D, Luo H, Zeng Y, Fu P and Liu C: Pharmacokinetics, tissue
distribution, excretion, and antiviral activity of pegylated
recombinant human consensus interferon-α variant in monkeys, rats
and guinea pigs. Regul Pept. 173:74–81. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cheng J: New progress in therapy of
patients with chronic hepatitis C. Zhonghua Lin Chuang Gan Ran Bing
Za Zhi. 4:1–5. 2010.(In Chinese).
|
|
17
|
Bajaire BJ, Paipilla DF, Arrieta CE and
Oudovitchenko E: Mixed vascular occlusion in a patient with
interferon-associated retinopathy. Case Rep Ophthalmol. 2:23–29.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
McHutchison JG, Lawitz EJ, Shiffman ML,
Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff
ER, et al: Peginterferon alfa-2b or alfa-2a with ribavirin for
treatment of hepatitis C infection. N Engl J Med. 361:580–593.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Dienstag JL and McHutchison JG: American
Gastroenterological Association medical position statement on the
management of hepatitis C. Gastroenterology. 130:225–230. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Hadziyannis SJ, Sette H Jr, Morgan TR,
Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr,
Bernstein D, Rizzetto M, et al: Peginterferon-alpha2a and ribavirin
combination therapy in chronic hepatitis C: A randomized study of
treatment duration and ribavirin dose. Ann Intern Med. 140:346–355.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Jacobson IM, Gordon SC, Kowdley KV,
Yoshida EM, Rodriguez-Torres M, Sulkowski MS, Shiffman ML, Lawitz
E, Everson G, Bennett M, et al: Sofosbuvir for hepatitis C genotype
2 or 3 in patients without treatment options. N Engl J Med.
368:1867–1877. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rodriguez-Torres M, Jeffers LJ, Sheikh MY,
Rossaro L, Ankoma-Sey V, Hamzeh FM and Martin P: Latino Study
Group: Peginterferon alfa-2a and ribavirin in Latino and non-Latino
whites with hepatitis C. N Engl J Med. 360:257–267. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Shiffman ML, Salvatore J, Hubbard S, Price
A, Sterling RK, Stravitz RT, Luketic VA and Sanyal AJ: Treatment of
chronic hepatitis C virus genotype 1 with peginterferon, ribavirin,
and epoetin alpha. Hepatology. 46:371–379. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Daw MA, Elasifer HA, Dau AA and Agnan M:
The role of hepatitis C virus genotyping in evaluating the efficacy
of INF-based therapy used in treating hepatitis C infected patients
in Libya. Virol Discov. 1:32013. View Article : Google Scholar
|
